Psychedelics EO May De-Risk Innovation, But Data Is Still King

By Joseph Tucker, Ph.D.

Psychedelics have generated significant excitement in recent years, driven by a growing understanding around their potential to treat a range of mental health conditions. However, this “renaissance” has been tempered by an underlying perception of risk among developers and investors.

Pressing challenges facing psychedelic-derived drugs are the still-uncertain regulatory and logistical processes that will be required for such therapies due to the profound mental and physical experiences they can induce, including hallucinations. These effects complicate placebo-controlled clinical trials and will necessitate complex, resource-intensive infrastructure before, during, and after treatment. Layered onto this is decades of cultural, political, and legal stigma, including outright prohibition, which has delayed progress.

This is why the Executive Order signed on April 18, 2026, represents an important signal for the field. It serves as a meaningful de-risking mechanism, enabling drug developers to focus on the questions that matter most: generating robust safety and efficacy data, and developing treatment models that can ultimately scale to broad patient access.

The Bar Has Not Been Lowered

A crucial point to recognize is that the Executive Order does not lower the bar for safety or efficacy. As in any therapeutic area, developers must still meet rigorous clinical, manufacturing, and regulatory standards to deliver products that physicians trust and patients can access.

Where the Executive Order makes its greatest impact is on time. Development timelines have long been one of the largest contributors to risk in this space. By introducing greater regulatory clarity and efficiency, it has the potential to accelerate progress meaningfully.

Specifically, the Executive Order addresses three key pillars that may accelerate drug development, potentially motivating investors and big pharma partners to take a closer look:

• Regulatory Predictability and Expedited Pathways: By directing the FDA to leverage the Commissioner’s National Priority Vouchers for breakthrough-designated psychedelic therapies and to establish clearer, expedited clinical pathways, the government is shortening the time from discovery to patient access. For companies at various stages, advancing IND-enabling studies or clinical trials, this clarity is invaluable, allowing capital and effort to be focused where they should be, on data generation and patient safety.
• Structured Access through “Right to Try”: Expanding “Right to Try” pathways introduce a formal, regulated framework for patients with serious mental health conditions to access investigational therapies. Importantly, it also enables the collection of real-world evidence, reducing pressure to fully optimize delivery models before clinical efficacy is established.
• Rescheduling Clarity: The directive for the Attorney General to review therapies for rescheduling following successful Phase 3 completion removes a major overhang. The risk that an approved therapy could remain constrained by Schedule I classification has long deterred institutional capital and strategic partnerships. This provision should directly alleviate that concern.

The Next Frontier: Scaling Beyond The “Psychedelic” Bottleneck

While the Executive Order is focused on the current wave of psychedelic therapies — many of which, like ibogaine, are associated with intense mind-altering, hallucinogenic effects and known safety considerations — it also has broader implications across the physiology-altering, neuroplastogenic landscape.

Inspired by psychedelics, researchers have been developing a new class of plasticity-inducing, non-hallucinatory compounds, which may provide the “Goldilocks” opportunity. Compounds capable of inducing neuroplasticity hold clear promise for patients suffering from mental health disorders, many of whom remain inadequately served by today’s treatment options, and these compounds offer the potential to provide the therapeutic benefit of a psychedelic without the burdens of the hallucinatory side effect.

For many in the field, this “next generation” of therapies have the potential to dramatically expand access and usability. The first wave of hallucination-inducing psychedelic-assisted therapies will likely require extensive clinical oversight, prolonged monitoring, and specialized infrastructure, factors that present meaningful challenges to scalability. While the Executive Order does not eliminate these constraints, it does remove key regulatory barriers, accelerating the research needed to better understand and harness neuroplasticity across the field. Seeing the first wave of treatments to pass through the bottleneck should allow more innovative treatments to follow.

A Turning Point For Patients

Ultimately, the most profound impact of this Executive Order is what it represents for patients living with severe mental health conditions such as treatment-resistant depression, PTSD, and anxiety. After decades of limited innovation in neuropsychiatric drug development, many patients have been left searching for alternatives on their own.

For the biotech industry, this moment brings long-awaited clarity. It reduces uncertainty, encourages investment, and creates a more defined pathway toward approval and commercialization.

At Enveric, we are committed to advancing our pipeline within this evolving framework. We believe that the combination of supportive policy and rigorous science will unlock a new generation of therapies delivering meaningful solutions to the millions of patients who urgently need them.

About The Author:

Joseph Tucker, Ph.D., CEO and Director at Enveric Biosciences, Inc. is a seasoned executive who has built several publicly traded biotechnology companies. Dr. Tucker was a founder and Chief Executive Officer of Stem Cell Therapeutics, which he took public on the TSX (TSX: SSS). Trillium Therapeutics (NASDAQ: TRIL, TSX: TRIL) acquired Stem Cell Therapeutics in 2013. Dr. Tucker also hasheld the position of Co-Founder and Chief Executive Officer at Epimeron Inc., a University of Calgary start-up acquired in the creation of Willow Biosciences Inc. (TSX: WLLW). At Willow, Dr. Tucker served as Executive Chairman and Chief Operating Officer. Prior to founding companies, Dr. Tucker was a healthcare analyst with two investment banks and also has worked in technology commercialization for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.